Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
RAP-219 by Rapport Therapeutics for Peripheral Neuropathic Pain: Likelihood of Approval
RAP-219 is under clinical development by Rapport Therapeutics and currently in Phase I for Peripheral Neuropathic Pain. According to GlobalData,...